Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07777120 | Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma | active not recruiting | — | 300 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 4 | Aug 19, 2026 |
| NCT02390869 | Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients(FIL_RENOIR12) | active not recruiting | Phase 3 | 128 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | active not recruiting | Phase 3 | 280 | Children's Oncology GroupNETWORK | 6 | Aug 19, 2026 | clinicaltrials |
| NCT02966756 | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 66 | AbbVieINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT03147612 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03876769 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients(CASSIOPEIA) | active not recruiting | Phase 2 | 121 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 19, 2026 | clinicaltrials |
| NCT05173961 | A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05480904 | Characterizing Sleep Among Long-term Survivors of Childhood Cancer | active not recruiting | — | 199 | St. Jude Children's Research HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05600894 | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm | active not recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 2 | Aug 19, 2026 | clinicaltrials |
| NCT06169267 | Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy | active not recruiting | Phase 3 | 113 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT00923013 | Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | active not recruiting | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02210078 | Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection | active not recruiting | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03198026 | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | active not recruiting | Phase 2 | 29 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03906292 | Frontline Asciminib Combination in Chronic Phase CML(CMLXI) | active not recruiting | Phase 2 | 125 | University of JenaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05831358 | Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program | active not recruiting | N/A | 201 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06733441 | A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma | active not recruiting | Phase 1 | 50 | Treeline Biosciences, Inc.INDUSTRY | 2 | Aug 18, 2026 | clinicaltrials |
| NCT07153796 | A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07456436 | Data-Driven Strategies for Patient Engagement About Cancer Clinical Trials | active not recruiting | — | 111 | University of Southern CaliforniaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03943901 | Split-Dose R-CHOP for Older Adults With DLBCL | active not recruiting | Phase 2 | 27 | University of Wisconsin, MadisonOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 121 | Hoffmann-La RocheINDUSTRY | 5 | Aug 17, 2026 | clinicaltrials |
| NCT05950165 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 37 | Cho Pharma Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE) | active not recruiting | Phase 2 | 313 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06042725 | MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 16 | Mayo ClinicOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06216158 | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 411 | University of Heidelberg Medical CenterOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT03502733 | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | active not recruiting | Phase 1 | 64 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03843294 | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma | active not recruiting | Phase 1 | 18 | Catherine BollardOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04013685 | Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | active not recruiting | Phase 1 | 155 | Orca Biosystems, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04537871 | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | active not recruiting | — | 350 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05150561 | Muscle Dysfunction in Patients With Haematological Diseases | active not recruiting | — | 216 | Rigshospitalet, DenmarkOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05428176 | A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors | active not recruiting | N/A | 332 | City of Hope Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05464823 | Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma | active not recruiting | N/A | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06685848 | Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion | active not recruiting | N/A | 24 | HemanextINDUSTRY | 2 | Aug 14, 2026 | clinicaltrials |
| NCT02577926 | The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia(Ruxo-BEAT) | active not recruiting | Phase 2 | 207 | RWTH Aachen UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03962127 | MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway | active not recruiting | — | 800 | Norwegian University of Science and TechnologyOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04113018 | Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 39 | Wake Forest University Health SciencesOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05675449 | A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma(MagnetisMM-20) | active not recruiting | Phase 1 | 59 | PfizerINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | active not recruiting | Phase 3 | 160 | PharmaEssentiaINDUSTRY | 9 | Aug 13, 2026 | clinicaltrials |
| NCT07413991 | Expressive Writing Program Among Young Adults With Blood Cancer | active not recruiting | N/A | 100 | Blood Cancer UnitedOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04468841 | Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma | active not recruiting | Phase 1 | 77 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04608487 | Axi-cel in CNS Lymphoma | active not recruiting | Phase 1 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05495464 | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | active not recruiting | Early Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | active not recruiting | Phase 1 | 37 | Incyte CorporationINDUSTRY | 8 | Aug 12, 2026 | clinicaltrials |
| NCT02756897 | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | active not recruiting | Phase 2 | 234 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02889523 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy(Epi-RCHOP) | active not recruiting | Phase 1 / Phase 2 | 214 | The Lymphoma Academic Research OrganisationOTHER | 2 | Aug 11, 2026 | clinicaltrials |
| NCT03220022 | Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas | active not recruiting | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03505762 | Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment | active not recruiting | Phase 2 | 80 | Wake Forest University Health SciencesOTHER | 1 | Aug 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials